Primecap Management CO Bei Gene, Ltd. Transaction History
Primecap Management CO
- $134 Billion
- Q3 2024
A detailed history of Primecap Management CO transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Primecap Management CO holds 4,974,289 shares of BGNE stock, worth $966 Million. This represents 0.84% of its overall portfolio holdings.
Number of Shares
4,974,289
Previous 4,986,289
0.24%
Holding current value
$966 Million
Previous $711 Million
56.98%
% of portfolio
0.84%
Previous 0.52%
Shares
29 transactions
Others Institutions Holding BGNE
# of Institutions
249Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.05 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.25 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.01 Billion26.65% of portfolio
-
Baillie Gifford & CO3.71MShares$720 Million0.64% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.7MShares$525 Million0.07% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $20.1B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...